Current filters:

RebifMerck KGaA

1 to 9 of 58 results

Merck KGaA improves guidance with strong third quarter results

Merck KGaA improves guidance with strong third quarter results


Germany’s Merck KGaA (MRK: DE) has posted solid organic revenue growth of 4.7% for the third quarter…

BiotechnologyErbituxEuropeFinancialMerck KGaAMerck SeronoPharmaceuticalRebif

Appeals Court rules against EMD Serono over Rebif deal with Pfizer


Germany's Merck KGaA (MRK: DE) says that a Pennsylvania appeals court has ruled against Merck in deciding…

BiotechnologyEMD SeronoLegalMarkets & MarketingMerck KGaANeurologicalNorth AmericaPfizerPharmaceuticalRebif

US FDA approves Merck KGaA's Rebif Rebidose


German drug major Merck KGaA's (MRK: DE) US subsidiary EMD Serono and pharma behemoth Pfizer (NYSE: PFE)…

BiotechnologyEMD SeronoMerck KGaANeurologicalNorth AmericaPfizerPharmaceuticalRebifRegulation

Expanded use for Merck Serono’s Rebif in EU


Merck Serono, the Switzerland-based division of Germany’s Merck KGaA (MRK: DE), says that that the…

EuropeMerck KGaAMerck SeronoNeurologicalPharmaceuticalRebifRegulation

Merck KGaA US units agree $44.3 million settlement with DoJ; Ranbaxy faces up to $1 billion fine?


Four US subsidiaries of German drug major Merck KGaA (MRK: DE) - Serono Laboratories, EMD Serono, Merck…

LegalMerck KGaAMerck SeronoNorth AmericaPharmaceuticalRanbaxy LaboratoriesRebif

1 to 9 of 58 results

Back to top